Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Tenecteplase (TNK) was found non-inferior to alteplase (ALT) for acute ischemic stroke (AIS). We sought to further elucidate the efficacy and safety of intravenous TNK versus ALT for AIS patients with large-vessel occlusion (LVO).
Methods: We systematically searched PubMed, Embase, Web of Science, and https://clinicaltrials.gov/ till 20 January 2024 for randomized controlled clinical trials (RCTs) comparing TNK with ALT in AIS patients with LVO. The quality of the included studies was estimated using the Cochrane Risk of Bias Tool. Pooled analysis and publication bias were conducted using RevMan 5.3 and Stata 15. Risk ratios (RRs) with 95% confidence intervals (95% CIs) were reported for each outcome measure. The primary outcome was excellent neurological recovery, which was defined as a modified Rankin Scale (mRS) score of 0-1 at 90 days, and safety outcomes included any parenchymal hematoma, sympomatic intracerebral hemorrhage, and 3-month death.
Results: Five RCTs enrolling 1,028 patients were included. There were no significant differences in terms of 90-day excellent neurological recovery (RR 1.18; 95% CI 1.00-1.40; = 0.05), good neurological recovery (RR 1.18; 95% CI 0.90-1.54; = 0.23), early neurological improvement (RR 1.00; 95% CI 0.57-1.77; = 1.00), or successful reperfusion (RR 1.15; 95% CI 0.93-1.44; = 0.20). In addition, no significant differences were observed in safety outcomes, including any parenchymal hematoma (RR 1.01; 95% CI 0.70-1.45; = 0.98), symptomatic intracerebral hemorrhage (RR 1.14; 95% CI 0.62-2.10; = 0.68), or 3-month mortality (RR 1.22; 95% CI 0.52-2.84; = 0.65).
Conclusion: TNK is an alternative to ALT for thrombolysis in AIS patients with confirmed LVO, offering lower cost and easier administration without increasing safety concerns.
Systematic Review Registration: https://www.crd.york.ac.uk/prospero/, identifier CRD42024540215.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11963696 | PMC |
| http://dx.doi.org/10.3389/fneur.2025.1487711 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Intravenous thrombolysis before endovascular therapy for acute ischemic stroke due to tandem lesions: a systematic review and meta-analysis.
Neurosurg Rev
September 2025
Department of Neurology, Radiology & Neurosurgery, University of Iowa Hospitals and Clinics, Iowa, IA, USA.
The role of intravenous thrombolysis (IVT) in patients with tandem lesions (TL) undergoing endovascular thrombectomy (EVT) for acute ischemic stroke (AIS) remains a subject of ongoing debate. The substantial clot burden and the potential need for periprocedural antiplatelet therapy during emergent carotid stenting (CAS) add to the complexity of treatment decisions. This study aims to systematically review and meta-analyze the literature to evaluate the comparative safety and efficacy of IVT plus EVT versus EVT alone in AIS patients with TL.
View Article and Find Full Text PDFSpontaneous Recanalization of Left Middle Cerebral Artery Occlusion Beyond the Thrombolysis Window.
J Craniofac Surg
September 2025
Weifang People's Hospital, Shandong Second Medical University, Weifang, China.
Large vessel occlusion (LVO)-induced acute ischemic stroke (AIS) manifests with abrupt onset and critical severity, primarily caused by cerebral artery atherosclerosis or cardiogenic embolism leading to luminal stenosis or occlusion. The authors report a case of acute massive cerebral infarction caused by occlusion of the left middle cerebral artery (MCA) and missed the time window for thrombolysis, in which spontaneous recanalization of the MCA was achieved after 1 week of conservative treatment. After 2 months of rehabilitation training, neurological functions and other symptoms significantly improved.
View Article and Find Full Text PDFA novel automated CT biomarker to predict outcomes in acute ischemic stroke: net water uptake.
Front Neurol
August 2025
McGovern Medical School, Department of Neurology, The University of Texas Health Houston, Houston, TX, United States.
Background: Recent trials of large core thrombectomy have shown that our traditional understanding of infarct characteristics and reperfusion benefit may be incomplete for patients with acute ischemic stroke (AIS). The Alberta Stroke Program Early CT Score (ASPECTS) has wide inter-rater variability, and modern studies have also shown that reperfusion therapies can benefit some patients regardless of the ASPECTS. Reproducible imaging metrics that account for the degree of hypo-attenuation on non-contrast computed tomography (NCCT) may be better suited to guide treatments.
View Article and Find Full Text PDFMedical Artificial Intelligence: Opportunities and Challenges In Infectious Disease Management.
Curr Med Chem
August 2025
Department of Pharmaceutical Sciences, Shalom Institute of Health and Allied Sciences, Sam Higginbottom University of Agriculture, Technology and Sciences, Allahabad, 211007, Uttar Pradesh, India.
Globally, millions of individuals suffer from infectious diseases, which are major public health concerns caused by bacteria, fungi, viruses, or parasites. These diseases can be transmitted directly or indirectly from person to person, potentially leading to a pandemic or epidemic. Several advancements have been made in molecular genetics for infectious disease management, which include pharmaceutical chemistry, medicine, and infection tracking; however, these advancements still lack control over human infections.
View Article and Find Full Text PDFmiRNA-494 in Lymphocytes: A Promising Biomarker for Acute Ischemic Stroke.
Rev Neurol
August 2025
Institute of Cerebrovascular Diseases Research and Department of Neurology, Xuanwu Hospital of Capital Medical University, 100053 Beijing, China.
Background: microRNA-494 (miRNA-494) plays a key role in neuroinflammation following cerebral ischemia. We aimed to assess miRNA-494 levels as a biomarker for predicting acute ischemic stroke (AIS) severity and outcomes.
Methods: miRNA-494 levels in peripheral lymphocytes were measured using reverse transcription-quantitative polymerase chain reaction.